Author/Authors :
Verschoor، نويسنده , , E.J. and van Vliet، نويسنده , , A.L.W. and Egberink، نويسنده , , H.F. and Hesselink، نويسنده , , W. and van Alphen، نويسنده , , W.E. and Joosten، نويسنده , , I. and Boog، نويسنده , , C.J.P. and Horzinek، نويسنده , , M.C. and de Ronde، نويسنده , , A.، نويسنده ,
Abstract :
Crandell feline kidney cells and feline thymocytes, either feline immunodeficiency virus (FIV) infected or uninfected, were fixed with paraformaldehyde and used to vaccinate cats. The cells were mixed with a 30:70 water/mineral oil emulsion containing 250 μg ml−1 N-acetyl-d-glucosaminyl-β-(1–4)-N-acetyl-muramyl-l-alanyl-d-isoglutamine. Eighteen specific pathogen-free cats were vaccinated three times with 3-week intervals and challenged 21 days after the final boost with a low dose of the homologous FIV-UT113 strain. Eight out of ten cats that had received FIV-infected cell vaccines developed significant anti-FIV antibody titres to the envelope and core antigens. Neutralizing antibodies were detectable at the moment of challenge in the sera of these animals. Within 5 weeks after challenge 15 out of 18 cats became viraemic. Three animals, two that had been vaccinated with FIV-infected thymocytes and did not develop antibody, and one that had received an uninfected thymocyte preparation, remained uninfected for 6 months. Upon rechallenge of the three animals, two again resisted infection; these cats had been immunized with the infected and the uninfected thymocyte preparations, respectively.
